University of California, Los Angeles

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).

897 total trials 158 currently recruiting 622 completed early-phase tilt top decile by trial count

University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.

University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.

Top-decile sponsor footprint

University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

897 total, page 9 of 18

COMPLETED NA

Effect of Pomegranate Juice Consumption on the Health of Mothers and Infants During Breastfeeding

NCT04341961

COMPLETED NA

Adolescent Cancer Telemedicine for Pain Management

NCT03603886

COMPLETED

Improving the Diagnosis of Common Variable Immune Deficiency

NCT03335605

TERMINATED Phase 1

Quadratus Lumborum Nerve Blocks for Myomectomies

NCT03935815

COMPLETED Phase 1

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144

TERMINATED Phase 4

Comparing Preoperative Injection of Mitomycin-C vs. Intraoperative Injection of Mitomycin-C vs. Topical Application of Mitomycin-C (Conventional Use) in Trabeculectomy

NCT03875911

COMPLETED NA

Shared Decision Making in Diabetes Prevention for Women With a History of GDM

NCT03766256

COMPLETED Early Phase 1

IPACK and Adductor Canal Catheter Patient Outcomes for TKAs?

NCT03774966

COMPLETED NA

ECigs, Inflammation and Oxidative Stress

NCT03823885

COMPLETED NA

The Effects of Manipulating Expectations in a Gratitude Intervention

NCT03784001

COMPLETED NA

Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects

NCT04591782

COMPLETED NA

Transcranial Magnetic Stimulation and Tobacco Use Disorder

NCT03827265

COMPLETED NA

Treatment for Affect Dimensions

NCT03439748

COMPLETED NA

The Safety and Intake Rate of a Natural Compound Arctigenin in Healthy Men

NCT03703388

COMPLETED NA

The Cardiovascular Effects of Electronic Hookah Vaping

NCT03690427

COMPLETED NA

Sleep Without Insomnia or The Use of Chronic Hypnotics

NCT03687086

COMPLETED NA

High Frequency Oscillation in Pediatric Epilepsy Surgery

NCT03790280

COMPLETED Phase 1

Technology Enhanced Family Treatment

NCT03913013

COMPLETED NA

Deep Brain Stimulation with LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT03347084

COMPLETED NA

Randomized Controlled Trial of Standard ERP and OC-Go

NCT03601312

COMPLETED NA

Postpartum Care Timing: A Randomized Trial

NCT03733405

COMPLETED NA

Optimizing Exposure Therapy With Mental Rehearsal

NCT03934385

COMPLETED NA

Guided Meditation and Stress-Induced Eating

NCT03707197

COMPLETED NA

Patient Portal - Flu Reminder Recall

NCT03666026

COMPLETED NA

Treating Phobia With Multivoxel Neuro-reinforcement

NCT03655262

COMPLETED Phase 2

Ibudilast for the Treatment of Alcohol Use Disorder

NCT03594435

COMPLETED

A Clinical Decision Support Trial to Reduce Intraoperative Hypotension

NCT04062994

COMPLETED NA

Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke

NCT03574038

COMPLETED NA

Effect of Strawberry Consumption on the Microbiome

NCT04217122

COMPLETED NA

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

NCT03455569

COMPLETED Phase 2

Cefixime for Alternative Syphilis Treatment

NCT03660488

TERMINATED Early Phase 1

Leucine for Depression Study (L-DEP)

NCT03557684

COMPLETED NA

MyLife: A Digital Health Coaching Program

NCT03529903

COMPLETED NA

The STOP-HPV Trial 2: Performance Feedback Intervention

NCT03599570

COMPLETED NA

The STOP-HPV Trial 1: Communication Intervention

NCT03599557

COMPLETED Phase 2

Ibudilast and Withdrawal-Related Dysphoria

NCT03489850

COMPLETED NA

Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers

NCT03538574

COMPLETED NA

SMART Program in Irritable Bowel Syndrome (IBS)

NCT03454386

COMPLETED NA

Brief Intervention by Community Health Workers for Unhealthy Drinking in Latinos

NCT03301064

COMPLETED NA

Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response

NCT03253081

TERMINATED Early Phase 1

N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization

NCT03451435

COMPLETED NA

Pilot Test of Patient Decision Aid for Opioid Use Disorder

NCT03394261

COMPLETED NA

Acupuncture vs TENS for Gag Reflex

NCT04757948

COMPLETED NA

Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training

NCT03503669

COMPLETED NA

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

NCT03726151

COMPLETED

Platelet Function on Abacavir and Tenofovir

NCT03081572

COMPLETED NA

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

NCT03759236

COMPLETED Early Phase 1

Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke

NCT03296852

TERMINATED NA

Effects of Phytonutrients on Vascular Health and Skin in Obese Males

NCT03496584

COMPLETED NA

Laboratory-based Hypnosis Intervention on Pain Responsivity in Adolescents With Sickle Cell Disease

NCT02987725

← Previous Page 9 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 112
Phase 2 82
Phase 3 22
Phase 4 76

What is open in the University of California, Los Angeles pipeline

158 recruiting of 897 indexed (18% open); 622 completed (69%).

Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).

Top condition: Depression (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Los Angeles: open-pipeline peers nationwide

Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20% Total trials Recruiting share University of California, Los AngelesIndiana UniversityHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterConvaTecEndologixNational Institute on Deafness and Other Communication Disorders (NIDCD)NICHD Pelvic Floor Disorders Network
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 897 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of California, Los Angeles page

897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.

  • 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.